 PROTOCOL No: 1237 -0064 – Boehringer Ingelheim COPD  Study  
   
 
 
 
   
 
Randomized Pragmatic Clinical Trial in a Community -Based Setting 
Comparing STIOLTO® RESPI[INVESTIGATOR_160031]® vs. ICS-LABA plus LAMA in Patients 
with COPD  
The AIRWISE  Study : Assessment In a R eal World setting of the effect of Inhaled 
Steroid -based triple therapy versus the combination of tiot ropi[INVESTIGATOR_771837].   1237 -0064 
  
 
 
 
Fax:  
 
 
May 9, 2018 
Ve
rsion 2.0  
 
 
   
 
This document and its contents are the property of Boehringer Ingelheim  
and are confidential.  Unauthorized copying or use is prohibited. 
Doc. No.: c23740530-01

Doc. No.: c23740530-01

Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  3 
 Study Physician Agreement : 
I have read the protocol “Randomized Pragmatic Clinical Trial in a Community -Based Setting 
Comparing STIOLTO® RESPI[INVESTIGATOR_160031]® vs. ICS- LABA plus LAMA in Patients with COPD ” and 
agree to ensure that all staff members involved in the conduct of this  study are informed of their 
obligations in meeting the commitments in accordance with it . 
I acknowledge that I am responsible for overall study conduct. I agree to personally conduct or 
supervise the described pragmatic trial. 
 
Signature:          [CONTACT_1782]:     
 
Print Name:         
 
   
[CONTACT_771895]. No.: c23740530-[ADDRESS_1059688] OF ABBREVIATION S ............................................................................................. 11 
1 INTRODUCTION ...................................................................................................... 13 
1.1 Background and Rationale  .................................................................................................................................. 13 
2 STUDY OBJECTIVES  ............................................................................................... 15 
2.1 Primary Objectives  ................................................................................................................................................ 15 
2.1.1  Primary Objective Definitions  .......................................................................................................................................... 15 
2.2 Secondary Objectives  ............................................................................................................................................ 15 
3 STUDY ENDPOINTS  ................................................................................................. 16 
4 STUDY DESIGN ........................................................................................................ 17 
4.1 Overview  .................................................................................................................................................................... 17 
4.2 Practice and Participant Selection  ................................................................................................................... 17 
4.2.1  Physician Practice Eligibility  ............................................................................................................................................ 17 
4.2.2  Participant Recruitment and Eligibility  ....................................................................................................................... 18 
4.2.3  Participant Inclusion Criteria  ........................................................................................................................................... 18 
4.2.4  Participant Exclusion Criteria  .......................................................................................................................................... 18 
4.2.5  Participant Enrollment  ........................................................................................................................................................ 19 
4.2.6  Patient Randomization  ........................................................................................................................................................ 19 
FIGURE 1: SCHEMATIC OF STUDY DESIGN ............................................................... 20 
5 STUDY PROCEDURES  ............................................................................................. 21 
5.1 Enrollment Procedures  ........................................................................................................................................ 21 
Doc. No.: c23740530-[ADDRESS_1059689] TM (CAT)  ..................................................................................................................................... 22 
5.4 Study Period  ............................................................................................................................................................. 22 
5.5 Final Visit/EOS  ......................................................................................................................................................... 22 
  
5.7 Withdrawals  ............................................................................................................................................................. 23 
5.7.1  Physician Practices  ............................................................................................................................................................... 23 
5.7.2  Participants  .............................................................................................................................................................................. 23 
6 STATISTICAL METHODS  ....................................................................................... 23 
6.1 Analysis Overview  .................................................................................................................................................. 23 
6.2 Study Populations ................................................................................................................................................... 24 
6.2.1  Analysis Populations  ............................................................................................................................................................ 24 
6.2.2  Safety Population  ................................................................................................................................................................... 24 
6.3 Sample Size Determination .................................................................................................................................  25 
6.3.1  Power and Sample Size for Primary Objective  ......................................................................................................... 25 
6.3.2  Randomization and Blinding  ............................................................................................................................................ 25 
6.3.3  Interim Analysis  ..................................................................................................................................................................... 25 
6.4 Effectiveness Analysis  ........................................................................................................................................... 25 
6.5 Patient Reported Outcome ( PRO ) Analysis ................................................................................................... 26 
6.6 Safety Analysis  ......................................................................................................................................................... 26 
 
  
  
  
6.8 Missing Data  ............................................................................................................................................................. 29 
7 AE REPORTING  ....................................................................................................... 29 
7.1 AEs  ................................................................................................................................................................................ 30 
7.2 SAEs.............................................................................................................................................................................. 31 
7.2.1  Reporting Period of SAEs  ................................................................................................................................................... 31 
7.3 Pregnancy  .................................................................................................................................................................. 32 
Doc. No.: c23740530-01

Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  6 
 8 DATA COLLECTION  ............................................................................................... 32 
8.1 Data Sources  ............................................................................................................................................................. 32 
8.2 eCRFs/EDC  ................................................................................................................................................................. 33 
8.3 Database Development  ........................................................................................................................................ 33 
8.4 Data Quality Assurance  ........................................................................................................................................ 33 
9 STUDY MANAGEMENT  .......................................................................................... 34 
9.1 Regulatory and Ethical Consideration  ............................................................................................................ 34 
9.1.1  IRB/ Independent Ethics Committee (IEC)  ................................................................................................................. [ADDRESS_1059690] Retention and Access  ............................................................................................................................. 35 
10 PUBLICATION OF STUDY RESULTS  .................................................................... 35 
TABLE 1: TIME AND EV ENTS SCHEDULE  .................................................................. 36 
TABLE 2: SAMPLE SIZE CALCULATIONS  .................................................................. 37 
APPENDIX A: COPD ASS ESSMENT TESTTM (CAT)  ..................................................... 38 
SUMMARY OF AMENDMENTS AND UPDATES  .......................................................... 39 
 
Doc. No.: c23740530-01
Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  7 
 SYNOPSIS  
 
Title:  Randomized Pragmatic Clinical Trial in a Community -Based Setting Comparing STIOLTO® 
RESPI[INVESTIGATOR_160031]® vs. ICS-LABA plus LAMA in Patients with COPD  
Study Name /Brief Title : Assessment In a Real World setting of the effect of Inhaled Steroid -based triple 
therapy versus the combination of tiotropi[INVESTIGATOR_771838] ( COPD ) Exacerbations  [AIRWISE]  
Sponsor:  Boehringer Ingelheim 
Trea tment : Stiolto ® Respi[INVESTIGATOR_96862] ® 
Active Ingredient : Tiotropi[INVESTIGATOR_1893] & olodaterol 
Comparator Product:  Inhaled Corticosteroid plus Long -acting beta agonists combination plus Long- acting 
muscarinic antagonists (ICS  plus LABA plus LAMA )  (Triple Therapy)  
Protocol No.:   1237-0064 
Study Physicians :  Approximately 400 physicians  who actively manage adult  patients  in the target 
indication, chronic obstructive pulmonary disease ( COPD).   
Country:  [LOCATION_002] (US)  
Patients: Adults (40 years of age or older) with COPD who are currently on long -acting muscarinic 
antagonist (LAMA) or long -acting beta agonist (LABA) or inhaled corticosteroid (ICS)/LABA maintenance 
therapy , and whose treatment is not controlled on the current medication regime n as determined by [CONTACT_24201]. 
Anticipated enrollment for this study is approximately 3200 patients , with approximately 1600 patients 
enrolled in each group. Patients will be randomized to either Stiolto Respi[INVESTIGATOR_771839] (triple  therapy) made up of the combination of any approved drugs that their physician chooses. 
Study Objectives : The objectives of this study are as follows:  
1.) The primary objective of this pragmatic study is to compare the time to first moderate or severe 
COPD exacerbation in patients , not controlled on their current therapy, randomized to Stiolto 
Respi[INVESTIGATOR_771840] 12 months of treatment. 
2.) The secondary objectives of this study are:  
a. To compare the annual rate of moderate or severe COPD exacerbations for patients on 
Stiolto Respi[INVESTIGATOR_771841]. 
b. To compare the time to first severe COPD exacerbation  in both treatment arms.   
c. To compare the annual rate of severe COPD exacerbations in both treatment arms.  
d. To compare the proportion of patients with moderate or severe COPD exacerbations in both 
treatment arms.  
 
 
 
 
 
 
Doc. No.: c23740530-01

Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  8 
 Study Endpoints:  
Primary endpoint : time to first moderate or severe chronic obstructive pulmonary disease (COPD) 
exacerbation over  12 months of treatment  
 
Secondary endpoints : 
• Annual rate of moderate or severe chronic obstructive pulmonary disease ( COPD) exacerbations 
• Time to first severe chronic obstructive pulmonary disease ( COPD) exacerbation  over the 12 
month observation period 
• Annual rate of severe chronic obstructive pulmonary disease ( COPD) exacerbations 
• Proportion of patien ts with moderate or severe chronic obstructive pulmonary disease ( COPD ) 
exacerbations over the 12 month observation period  
 
 
  
  
  
Study Design:   This is a pragmatic randomized open label active controlled parallel group design trial 
conducted in a real -world, community- based practice setting  for a fixed duration of 12 months  of treatment .  
All participating patients will already be on LAMA, LABA or ICS/LABA  for COPD , but will have been 
determined by [CONTACT_771872] .  Patients enrolled in the study 
will be randomized to  either Stiolto Respi[INVESTIGATOR_771842] (triple therapy) and provided 
with a prescription for the assigned treatment.   
Inclusion and exclusion criteria are minimally restrictive and there ar e few study -specific evaluations.  Study 
physicians will follow and treat patients according to their routine clinical practice and judgment.  Clinical 
and healthcare claims data will be collected from  study patients for  [ADDRESS_1059691] (e -mail, phone, contact [CONTACT_771873], receipt 
of records) that occur as part of standard clinical practice over the course of the study.  However, the only 
required study visits are a  baseline visit and a final end of study (EOS) visit at 12 months.   
Patient Selection:  
Inclusion Criteria :   
Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study: 
Priority will be given to p atients actively enrolled in an  affiliated health plan.  
• COPD diagnosis as defined by [CONTACT_5989] 
• Currently on one of the following maintenance therapi[INVESTIGATOR_014]: 
o LAMA monotherapy  
Doc. No.: c23740530-01

Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  9 
 o LABA monotherapy  
o ICS/LABA ( Fixed Dose Combination ( FDC )) 
• Physician  determination that patient is  not controlled on current pharmacotherapy  
• Adult patient  40 years of age  or older at time of study enrollment 
• Willingness and ability to understand and provide  documented Informed Consent Form (ICF) and 
Health Insurance Portability and Accountability Act (HIPAA) Authorization Form prior to 
commencement of any study required assessments , either directly or through Legally Authorized 
Representative.  
Exclusion Criteria: 
Patients presenting with any of the following  exclusion criteria will not be eligible for enrollment into the 
study: 
• Currently on LAMA/LABA (free or FDC) or triple therapy  (ICS plus LABA plus LAMA) 
• Contraindication to any study medications (LAMA, LABA or ICS) 
• Documented diagnosis of current asthma 
• Pregnant or nursing women 
 
Study Procedures: 
• Study physicians will identify elig ible patients for participation. 
• Study physicians will obtain written informed consent and patients will be randomized to either 
Stiolto Respi[INVESTIGATOR_771843]. 
• Study physicians will collect demographic, clinical  and COPD history  data on electronic C ase 
Report Forms (eCRFs) at baseline.  
• A complete blood count ( CBC ) including differential white cell count  will be drawn at baseline.  In 
the event that a CBC is not available at baseline, laboratory results within 12 months of baseline will 
be accepted.  
• The COPD Assessment TestTM (CAT ) symptom score will be assessed  at baseline.  
• Study physicians will collect patient data ( exacerbations, targeted  medication changes, selected 
adverse events (AEs)  (AEs leading to study treatment discontinuation, dose modification, or trial 
withdrawal) ) during any patient office visits  or other patient contact [CONTACT_78482] 12 months the 
patient is on study and enter it via an electronic data capture (EDC) system.  Any Serious A dverse 
Events (SAEs), including COPD exacerbat ion SAEs , will be collected via paper system . 
• Clinical data collection at the EOS visit at 12 months will include exacerbations, targeted 
medication changes, selected AEs and any SAEs.  
•  
 
 
 
 
Study Duration:   Patients will be on study and followed for [ADDRESS_1059692] clinical 
data.  
Patient Reported Outcomes ( PROs ):  The CAT will be administered at  baseline to  provide a simple and 
reliable measure of health status in COPD and assist patients and their physicians in quantifying the impact 
of COPD on the patient’s health  at baseline .   
Doc. No.: c23740530-01

Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  10 
 Effectiveness Analysis :  The primary effectiveness analysis will assess time to first moderate or severe 
COPD exacerbation (as prospectively collected in the eCRF) of Stiolto Respi[INVESTIGATOR_771844] .  
A Cox proportional hazards model will be used to compare treatments.   
Secondary /Sensitivity  Analyses:  As a secondary effectiveness objective, the annual rate of moderate or 
severe exacerbations will also be calculated and compared between treatment groups.   Other secondary 
analyses include  evaluation of severe COPD exacerbations for time to first exacerbation and annual rate, 
proportion of patients with moderate or severe COPD exacerbations,  sensitivity analyses relating to 
exacerbation definition and source data, and sensitivity analyses relating to generalizability  of the study 
population.   
 
 
 
 
 
Safety:   All SAEs reported by [CONTACT_771874].  Selected AEs , e.g. AEs leading to study treatment discontinuation, dose 
modification , or trial withdrawal , will be collected on the eCRF during the  study. D uring extraction of data 
from the claims database, any identified SAEs will be reported  if not already collected on SAE form . 
 
  
Doc. No.: c23740530-[ADDRESS_1059693] 
  
Doc. No.: c23740530-[ADDRESS_1059694]  
MedDRA  Medical Dictionary for  Regulatory Activities  
PP Per Protocol 
PRO  Patient Reported Outcome 
PT Preferred Term  
PV Pharmacovigilance  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SM Service Mark  
SMQ  Standardized Medical Queries  
SOC  System Organ Class  
T2DM  Type 2 Diabetes Mellitus  
TM Trademark  
US [LOCATION_002]  
WISDOM  Withdrawal of Inhaled Steroids during Optimized 
Bronchodilator Management 
 
Doc. No.: c23740530-01
Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  13 
 1 INTRODUCTION 
1.1 Background and Rationale 
Chronic obstructive pulmonary disease (COPD) is a chronic lung disease characterized by 
[CONTACT_771875] a gradual loss in lung 
function.[ADDRESS_1059695] leading cause of 
deaths in the [LOCATION_002] (US) in 2011.2  However, a majority of the patients (>50%) with low 
pulmonary function are unaware of their COPD condition.3  This under diagnosis poses 
challenges in comm unity clinical practice , resulting in inappropriate patient management.  
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends classifying 
patients for treatment based on assessment of existing symptoms, severity of airflow limitation, 
and history of exacerbations .[ADDRESS_1059696]-bronchodilator forced expi[INVESTIGATOR_31737] (FEV1)/forced vital 
capacity (FVC) <0.[ADDRESS_1059697] (LAMA) and a long- acting beta agonist (LABA) has been recommended in patients 
whose COPD is not suf ficiently controlled with mono - bronchodilator therapy.  Clinical trials 
examining combination treatment with LAMA and LABA have shown long term improvements 
in lung function, symptom scores, and exacerbations in patients with moderate to very severe COPD.
6,7  Further, the convenience of fixed dose combination (FDC) products might provide an 
improved patient- centered approach that enhances patient acceptance and adherence to dual 
                                                        
 
1 Dewar M , Curry W. Chronic Obstructive Pulmonary Disease: Diagnostic Considerations. Am Fam  Physician. 
2006 Feb 15;73(4):669- 676. 
2 Hoyert DL, Xu JQ. Deaths: preliminary data for 2011.  Natl Vital Stat Rep . 2012;  61(6):1 -65. Hyattsville, MD: 
National Center for Health Statistics.  2012 
3 Center for Disease Control and Prevention. What is COPD? Available at http://www.cdc.gov/copd/index.htm.  
Accessed on January 20 , 2015.  
4 Global Strategy for the Diagnosis, Management and Prevention of COPD , Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) 2017. Available from: http://goldcopd.org . Accessed on March 4, 2017.  
5 Mapel DW , Dalal AA , Johnson P , et al. A clinical study of COPD severity assessment by [CONTACT_771876][INVESTIGATOR_038]. Am J Med.  2015. doi: 10.1016/j.amjmed.2014.12.018.  
6 Vogelmeier C, Kardos P, Harari S, et al. Formoterol mono- and combination therapy with tiotropi[INVESTIGATOR_771845]:   a 6 month study. Respir Med . 2008;102:1511- 1520.  
7 Tashkin DP, Pearle J, Iezzoni D, et al. Formoterol and tiotropi[INVESTIGATOR_771846]. COPD. 2009;6:17- 25. 
Doc. No.: c23740530-01
Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  14 
 bronchodilator therapy and reduces copay burden to the patient.  Stiolto ® Respi[INVESTIGATOR_96862] ® is an FDC  
containing tiotropi[INVESTIGATOR_1890] (a LAMA) and olodaterol (a LABA) that was approved by [CONTACT_4469] ( FDA ) in May of 2015.  Multiple randomized controlled trials have 
demonstrated that the Stiolto Respi[INVESTIGATOR_771847]. 
GOLD 2017 does not recommend the use of triple combination therapy (LABA/inhaled 
corticosteroid ( ICS) + LAMA) except potentially in a subset of patients in group D (high risk for 
exacerbation/high symptom scores).  On the other hand, long-acting bronchodilators, including 
the combination of LAMA and LABA, are recommended as options in groups B (low risk  for 
exacerbation /high symptoms s cores ), C (high risk  for exacerbation /low symptoms  scores ) and D. 
However, m ultiple observational analyses of real -world data, including the preparatory analyses 
performed by  [CONTACT_771877], continue to show a high proportion of 
COPD patients being prescribed ICS- containing regimens, including triple therapy .  The 
magnitude of ICS prescribing seems to be contrary to the recommendations provided by  [CONTACT_328323] 
2017, and provides the impetus to perform the proposed study. 
While the benefits of ICS therapy are well documented across a broad spectrum of patients with 
asthma, their benefits in the COPD population appear to be more targeted to select patient 
phenotypes.  Specifically, the benefit appears to be most robust in patients with severe COPD with a history of frequent exacerbations or with an inflammatory/allergic component to their disease.  In addition, ICS therapy is associated with localized symptoms such as voice hoarseness 
and thrush, as well as systemic diseases such as upper respi[INVESTIGATOR_771848]. 
The Withdrawal of Inhaled Steroids during Optimized Bronchodilator Management ( WISDOM )
[ADDRESS_1059698] of withdrawing ICS in patients concurrently receiving LAMA/ LABA 
combination therapy.  In this randomized, double-blind, non-inferiority designed study the risk 
of moderate or severe exacerbations was similar between those who had their ICS withdrawn 
versus those who continued.  A logical follow-up research question from the WISDOM study is to assess patients who are not controlled on their current therapy of ICS- LABA, LABA alone or 
LAMA alone , to see if change in therapy to LAMA/LABA FDC  therapy is similar in effect to 
triple therapy.  S tudying the question in a manner that assesses patients as therapy is “stepped -
up” is reflective of  usual clinical practice and would provide valuable and relevant real-world 
evidence to both practicing clinicians and health care payers.  In addition, the GOLD 2017 
update specifically states that “more evidence is needed to draw conclusions on the benefits of 
triple therapy LABA/LAMA/ICS compared to LABA/LAMA .”  To this end, the proposed study, 
AIRWISE: Assessment In a Real World setting of the effect of I nhaled Steroid -based triple 
                                                        
 
8 Magnussen H, Disse B, Rodriguez -Roisin R, et al.  Withdrawal of Inhaled Glucocorticoids and Exacerbations of 
COPD. N Engl J Med. 2014;317:1285- 94. 
Doc. No.: c23740530-01

Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  15 
 therapy versus the combination of tiotropi[INVESTIGATOR_771849] E xacerbations , 
is a non-inferiority trial of community -based COPD patients randomized to either Stiolto 
Respi[INVESTIGATOR_771850] a physician decision to escalate therapy.   The decision to 
escalate therapy will be at the discretion of the treating physician.   Patients will be treated 
according to routine clinical practice and followed for clinical (exacerbations, etc.)  
 
 
[ADDRESS_1059699] moderate or severe 
COPD exacerbation in patients , not controlled on their current therapy, randomized to Stiolto 
Respi[INVESTIGATOR_771851] 12 months of treatment. 
2.1.1 Primary Objective Definitions  
For the purpose of this study, a COPD exacerbation is defined as a complex of lower respi[INVESTIGATOR_481204]/symptoms (increase or new onset) related to the underlying COPD, with duration of three 
days or more, requiring a prescription of antibiotics and/or systemic steroids and/or 
hospi[INVESTIGATOR_059] . 
A complex of lower respi[INVESTIGATOR_29343]/symptoms is defined as at least two of the following:  
• Shortness of breath 
• Sputum production (volume) 
• Change in sputum color 
• Cough 
• Wheezing  
• Chest tightness  
“Onset of exacerbation ” will be defined by [CONTACT_771878].  The “end of 
exacerbation ” will be decided by [CONTACT_716591].  
Exacerbations will be classified as follows: 
Moderate : Exacerbation requiring receipt of an exacerbation -related prescription of oral 
corticosteroids and/or antibiotic , but not requiring hospi[INVESTIGATOR_771852] : Exacerbation requiring COPD- related hospi[INVESTIGATOR_771853] s associated with COPD exacerbation, the information collected  should 
include the start date of all COPD -related hospi[INVESTIGATOR_602] , as well as the discharge date from the 
hospi[INVESTIGATOR_771854]. 
2.2 Secondary  Objectives  
The secondary objectives of this study include: 
Doc. No.: c23740530-01

Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  16 
 1) To compare the annual rate of moderate or severe COPD exacerbations for patients on 
Stiolto Resp imat with patients on triple therapy.  
2) To compare the time to first severe COPD exacerbation  in both treatment arms.  
3) To compare the annual rate of severe COPD exacerbations in both treatment arms.  
4) To compare the proportion of patients with moderate or severe COPD exacerbations in 
both treatment arms.  
[ADDRESS_1059700] moderate or severe chronic obstructive 
pulmonary disease  (COPD ) exacerbation over 12 months of treatment. 
Secondary endpoints include: 
• Annual rate of moderate or severe chronic obstructive pulmonary disease ( COPD ) 
exacerbation s 
• Time to first severe chronic obstructive pulmonary disease  ( COPD) exacerbation  
over the 12 month observation period 
• Annual rate of severe chronic obstructive pulmonary disease  ( COPD) exacerbations  
• Proportion of patients with moderate or severe chronic obstructive pulmonary disease 
(COPD) exacerbations  over the 12 month observation period 
 
 
  
  
  
 
Doc. No.: c23740530-01

Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  17 
 4 STUDY DESIGN 
4.1 Overview  
This is a pragmatic non-inferiority trial conducted in a real -world, community- based practice 
setting  for a fixed duration of 12 months of treatment .  All participating patients will already be 
on LAMA, LABA or ICS/LABA for COPD , but will have been determined by [CONTACT_771879].  No definition of ‘controlled’ will be offered by [CONTACT_771880]-world autonomous decisions.  Patients 
enrolled in the study will be randomized to either Stiolto Respi[INVESTIGATOR_771839] (triple therapy)  and provided with a prescription for the assigned treatment.  Study 
treatment s will be  open- label.  
In keepi[INVESTIGATOR_771855] a real -world setting, this 
study is naturalistic in design.  Inclusion and exclusion criteria are minimally restrictive and there are few study -specific evaluations.  Study physicians will follow and tre at patients 
according to their routine clinical practice and judgment.  Patients who enroll in the study agree to the release of health information and to answer questions about their health during the course 
of the study.  C linical and healthcare claims data will be collected from study patien ts for 
approximately  [ADDRESS_1059701] (e-mail, phone, contact [CONTACT_771873], 
receipt of records) that occur as part of standard clinical practice over the course of the study.  
The only required study visits are a baseline visit and a final end of study (EOS) visit at [ADDRESS_1059702] enrollment.  
4.2 Practice and Participant Selection  
4.2.1 Physician Practice Eli gibility  
Enrollment of approximately 400 physician sites with an adequate COPD population in the US is 
anticipated.  
Doc. No.: c23740530-01

Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  18 
 4.2.2 Participant Recruitment and  Eligibility  
Eligible participants include active COPD patients whose physicians determine that their COPD 
is not controlled on their current therapy (LAMA or LABA monotherapy or ICS/LABA).  
Patient recruitment and eligibility study procedures reflect the study ’s goal  of evaluating Stiolto 
Respi[INVESTIGATOR_771856] a real -world setting.  As such, patients will be recruited from the physician’s patient 
population in a manner that is representative of the real-world population who are currently 
receiving care within their practice.  
The determination that the patient is  not controlled on their current therapy, and therefore 
eligible for the study, is  at the discretion of the physician.  Once an eligible patient is enrolled, 
they will be randomized in sequence. 
It is anticipated that p articipant s will be  recruit ed from patients who are actively enrolled in an 
 of  or 
 health plan (hence forth referred to as  health plans).  To 
meet enro llment goals  recruitment will allow  non-  patients within enrolled physician 
practices , which may include Medicare/Medicaid patients.   
 
4.2.[ADDRESS_1059703] meet all of the following inclusion criteria to be eligible for enrollment into the 
study:  
Priority will be given to patients actively enrolled in an  affiliated health plan.  
• COPD diagnosis  as defined by [CONTACT_5989]  
• Currently on one of the following maintenance therapi[INVESTIGATOR_014] : 
o LAMA monotherapy  
o LABA monotherapy  
o ICS/LABA (FDC)  
• Physician  determination that patient is not controlled on current pharmacotherapy  
• Adult patient 40 years of age  or older at time of study enrollment 
• Willingness and ability to understand and provide documented Informed Consent Form 
(ICF) and Health Insurance Portability and Accountability Act (HIPAA) Authorization 
Form  prior to commencement of any study required  assessments, either directly or 
through Legally Authorized Representative. 
4.2.4 Participant Exclusion Criteria  
Patients presenting with any of the following exclusion criteria will not be eligible for enrollment into the study: 
Doc. No.: c23740530-01

Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  19 
 • Currently on LAMA/LABA (free or FDC) or triple therapy  (ICS plus LABA plus LAMA)  
• Contraindication to any study medications (LAMA, LABA or ICS)  
• Documented diagnosis of current asthma 
• Pregnant or nursing women 
Women of childbearing potential are not restricted in this trial, however it is expected that the 
investigator will assess the risks and benefits of the ass igned treatment as per the product label(s) 
and discuss this with any women of childbearing potential prior to providing the patient with the prescription for the assigned treatment. 
4.2.5 Participant Enrollment  
Anticipated enroll ment  for this study is approxima tely 3200 patients, with approximately 1600 
patients enrolled in each group. 
4.2.6 Patient Randomization 
Enrolled study patients will be randomized to either Stiolto Respi[INVESTIGATOR_771857] a 1:1 
ratio.  Once the study physician has determined patient eligibility and has enrolled them into the 
study in the Electronic Data Capture ( EDC ) system, the physician will receive the randomization 
assignment (Stiolto Respi[INVESTIGATOR_771858]) for that patient.   
Patient eligibility and randomization is depi[INVESTIGATOR_771859] (Figure 1) . 
Doc. No.: c23740530-01
Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  20 
 Figure 1: Schematic of Study Design 
Prior to  
Enrollment 
 
 
 
 
 
Enrollment 
 
 
 
 
 
 
 
  Visit 1  
Time Point  
(Baseline Visit)  
 
 
 
 
 Regular Care  
(On Study)  
     
 
 
 
End of Study  
(12 Month 
Visit)  
 
 
 
  
The only required study visits are Baseline and EOS at [ADDRESS_1059704] clinical practice.   See Table 1  for additional detail.  Screening Procedures  
• Identify eligible patients  
• Screen potential participants by [CONTACT_11548]   
• Obtain informed consent  
• Document  inclusion/exclusion criteria   
 
Baseline Assessments  
Document:  
• Demographics  
• COPD history  including exacerbations , pre-specified comorbid conditions, 
targeted medications , and reason for therapy escalation  
• Smoking status , blood eosinophil  results  
• COPD Assessment Test (CAT) responses  
 Randomize 3200 Participants Total  
 
Triple Therapy  
1600 participants  Stiolto Respi[INVESTIGATOR_96862]  
1600 participants  
On Study Follow -Up Assessments  
Patients seen according to routine clinical practice and physician judgment. Document:  
• Moderate to severe exacerbations, AE leading to discontinuation or dose 
modification of study treatment, or trial withdrawal, and  SAEs   
• Treatment changes, select medica tion changes, changes to study medication  
 
Final Assessments  
Document :  
• Moderate to severe exacerbations, AE leading to discontinuation or dose 
modification of study treatment, or trial withdrawal, SAEs   
• Treatment changes, select medication changes, changes to study medication  
 
 
Doc. No.: c23740530-[ADDRESS_1059705] ( IRB) approval of a site and study 
training, sites will begin patient enrollment.   The physician will make the decision reg arding the 
patient’s suitability for the study , and in order to maintain the real -world nature of the study, 
patients will be approached for potential enrollment into the study during routine office visits or 
other patient contact [CONTACT_771881].   
5.2 Baseline Visit  
Eligible patients interested in participating will provide written informed consent and be randomized to either Stiolto Respi[INVESTIGATOR_771860].  Data collection at 
baseline will include inclusion/ exclusion criteria as well as the data outlined in the sections 
below.  A blood sample will be drawn at the baseline visit for a complete blood count (CBC) including differential white cell count.  In the event that a CBC is not available at baseline, 
laboratory results within [ADDRESS_1059706] patient characteristics at each office visit 
as summarized in Table 1, either directly from the patient or abstracted from the patient’s chart , 
and enter them into the electronic Case Report Form  (eCRF ).  Baseline assessments will include 
demographic data, baseline clinical data (selected pre-specified comorbid conditions, CBC 
including a required baseline blood eosinophil count, and smoking status) as well as COPD and 
exacerbation history.  
5.2.[ADDRESS_1059707]
TM (CAT) to enable 
classification of patients by [CONTACT_941] 2017 GOLD A -D criteria  in conjunction with exacerbation 
history data.  Patients will complete the CAT and site study personnel will enter the  completed 
forms into the eCRFs. 
Doc. No.: c23740530-[ADDRESS_1059708] TM (CAT)  
The CAT is a short (8- item), simple, patient-completed questionnaire that measures the impact of 
COPD on a patient’s well -being and daily life.9  Patients rate the following items on a 6 -point (0 -
5) scale, where higher scores indicate worse  symptoms: Cough, Phlegm , Chest Tightness,
Breathlessness, Activities at Home, Confidence Leaving Home, Sleep  and Energy.  Scores from 
individual items are summed, yielding CAT scores ranging from [ADDRESS_1059709] a rigid visit schedule.  Patients 
will be followed  for 12 months according to their treating physician’s routine clinical practice 
and judgment.  On -study data collection during routine clinical visits or other contacts with 
patient , such as by [CONTACT_14223] e- mail, contact [CONTACT_771873] , or receipt of records , 
will include exacerbations , COPD targeted  concomitant medications, changes to study treatment, 
adverse events (AEs)  leading to study treatment  discontinuation, dose modification, or trial 
withdrawal and any Serious A dverse Events (SAEs).  It is anticipated that patients who are being 
treated for COPD will undergo medical evaluation at regular intervals; however, the only 
required study visits are baseline and EOS at 12 months. 
The study is anticipated to take 36 months from commencement of enrollment through data 
analysis and reporting. 
5.5 Final  Visit/EOS  
The EOS  visit will be [ADDRESS_1059710]. Eur Respir 
J. 2009;34:648- 654. 
Doc. No.: c23740530-01

Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  23 
 5.7 Withd
rawals 
5.7.1 Physician Practices  
Boehringer Ingelheim and/or the IRB reserve the right to terminate the study or participation of 
the study physicians at any time.  In such cases, data collection will end.  After the collected data 
is received, the participating study physicians will be compensated as contractually agreed.  
5.7.2 Participants 
Discontinuation will be based upon physician clinical determination and/or by [CONTACT_771882].  Participation in this study is voluntary, and all patients are free to terminate their participation at any time.  In the event of early termination of study participation, details regarding the 
discontinuation will be recorded.  Patients will be followed for the full [ADDRESS_1059711] moderate or severe COPD exacerbation.  
Null hypothesis for non- inferiority  
Doc. No.: c23740530-[ADDRESS_1059712] ratio (HR) of time to first 
moderate or severe COPD exacerbations in the Stiolto Respi[INVESTIGATOR_771861] 1.2.  The non-inferiority margin of 20% was based on practical 
considerations and kept consistent with the margin used in the W ISDOM  study.10  
H0: HR(Stiolto Respi[INVESTIGATOR_96862]/Triple Therapy) > = 1.2 
versus 
H1: HR(Stiolto Respi[INVESTIGATOR_96862]/Triple Therapy) < 1.2 
This will be addressed by [CONTACT_619725] 95% two -sided confidence interval 
for the HR with the non-inferiority  margin of 1.2. 
6.2 Study  Populations 
The following populations will be defined for analysis and reporting. 
6.2.1 Analysis Populations 
[IP_ADDRESS] Intent to Treat (ITT) Population  
The ITT population will include all randomized patients allocated to their original randomized 
treatment group , even if they switched  or discontinued study treatment . 
[IP_ADDRESS] Per Protocol (PP) Population 
No per-protocol set is defined and no analysis is planned.  A sensitivity analysis using on-
treatment exacerbations is described in Section 6.4. 
 
 
 
 
 
 
 
6.2.2 Safety  Population 
The safety population will include  all randomized patients who received a prescription  of any 
study treatment (Stiolto Respi[INVESTIGATOR_771858]).   
                                                        
 
10 Magnussen H, Disse B, Ro driguez -Roisin R, et al.  Withdrawal of Inhaled Glucocorticoids and Exacerbations of 
COPD. N Engl J Med. 2014;317:1285- 94. 
Doc. No.: c23740530-[ADDRESS_1059713] for survival analysis (with Schoenfeld’s 
formula for calculating the number of events), under the following assump tions: 
• Expected HR of moderate or severe COPD exacerbations of 1.0 between Stiolto 
Respi[INVESTIGATOR_771862]  
• 20% non- inferiority margin , with HR  boundary of 1.20 
• 42.5% of patients in the triple therapy arm have at least  one moderate or severe COPD 
exacerbation in 12 months 
• 90% power 
• One-sided  Type I error rate of 0.025 
• Randomization ratio 1:1 between treatment arms  
• Fixed trial duration with 12 month follow up 
• 15% drop-out rate during 12 months in both treatment arms 
6.3.2 Randomization and Blinding  
A  statistician independent from the study will create the randomization schedule to 
be loaded  into the EDC system.  Randomization will be validated by [CONTACT_771883] 3200 sample size plus 25% overrun.  Patients will be randomized in equal ratio to the two treatment arms and blocked randomization will be used.  The block size will be documented in the study report. 
This is an open- label randomized phase 4 trial, which is designed and conducted as a pragmatic 
trial, i.e. as a study in a real -world setting with minimal inclusion/exclusion criteria and few 
study-specific visits and procedures.  Blinding for this open- label pragmatic trial is n ot feasible;  
however selection bias will be eliminated via concealed treatment allocation through the EDC 
system.  The database for this pragmatic trial will not be blinded .  
6.3.3 Interim Analysis  
There is no interim analysis planned for this trial.  
6.4 Effectiveness  Analysis 
The effectiveness analysis will  address t he primary objective of this study : to determine whether 
Stiolto Respi[INVESTIGATOR_771863] -inferior to triple therapy as measured by [CONTACT_771884].  For the primary endpoint , COPD exacerbation defined as moderate or severe as 
collected in the eCRF will be used .   
Doc. No.: c23740530-[ADDRESS_1059714] moderate or severe COPD exacerbation, the Cox 
proportional hazards model with baseline ICS prior use as a covariate will be used to estimate the 
HR and the two -sided  95% Wald confidence interval .  
 
 
 
 
 
The p
rimary endpoint will also be analyzed for moderate or severe COPD exacerbations from 
different data sources: (1) claims data  only and (2) integrated eCRF/claims data.  
The details of all analyses will be fully described in the Statistical Analysis Plan ( SAP). 
6.5 Patient Reported Outcome ( PRO ) Analysis 
The impact of COPD on patients’ health and quality of life will be assessed at baseline via the 
CAT.  PRO analysis will be descriptive in nature and will not involve any statistical testing.  
Rather, summary  statistics will be used to describe  patient perceived health status impairment 
associated with COPD  at baseline, as well as potentially as an explanatory variable in any 
multivariate analyses or in subgroup analyses . 
6.[ADDRESS_1059715] 
SAE reporting process (See section 7.2).    
SAE data for analysis will be drawn from the Boehringer Ingelheim Safety Database.  
Analysis of non- serious AE s (leading to study treatment discontinuation or dose modification , or 
trial withdrawal)  will be performed on the study database, as these are entered in the eCRF only.  
Doc. No.: c23740530-01

Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  27 
 Safety analyses will be descriptive in nature.  No hypothesis testing is planned prospectively. 
AEs will be coded using the current version of the Medical Dictionary for Regulatory Activities 
(MedDRA) coding dictionary at the time of reporting, and recoded to the MedDRA version 
current at the time of database integration .  Summary tables and listings  will be produced to 
compare the incidence of AEs across treatment groups , by [CONTACT_9560] (PT )/System Organ 
Class ( SOC ) and also by [CONTACT_753394] (MedDRA Standardized Medical Queries (SMQ) or 
custom Boehringer Ingelheim searches termed Pharmacovigilance ( PV) endpoints).  All  AEs  
with an onset after the first dose of trial medication and up to [ADDRESS_1059716]-study period as appropriate.  
Doc. No.: c23740530-01

Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  28 
 
Doc. No.: c23740530-01

Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  29 
 6.8 Missing Data 
Missing data for exacerbation endpoints will not be imputed. 
 
7 AE REPORTING   
The study physician is responsible for monitoring the safety of participating patients.  All SAEs 
reported by [CONTACT_771885].  Selected AEs,  e.g. AEs leading to study treatment discontinuation, dose 
modification, or trial withdrawal, will also be collected on the eCRF during the study.  SAEs 
identified in patient- level review of hospi[INVESTIGATOR_771864] ( cf. section 6.6).  
Doc. No.: c23740530-[ADDRESS_1059717] a causal 
relationship with this treatment.   An AE can therefore be any unfavorable an d unintended sign 
(including an abnormal laboratory finding), symptom or disease temporally associated with the 
use of a medicinal product, whether or not considered related to the medicinal product. 
Only selected  non- serious  AEs will be collected in eCRF : events leading to study treatment 
discontinuation, dose modification, or trial withdrawal. 
Causal relationship of AEs 
Medical judgment should be used to determine the relationship, considering all relevant factors, 
including pattern of reaction, temporal relationship, de- challenge or re-challenge, confounding 
factors such as concomitant medication, concomitant diseases and relevant histo ry. 
Arguments that may suggest a reasonable causal relationship could be: 
• The event is consistent with the known pharmacology of the drug.  
• The event is known to be caused by [CONTACT_23320] . 
• A plausible time to onset of the event relative to the time of drug exposure. 
• Evidence that the event is reproducible when the drug is re-introduced. 
• No medically sound alternative etiologies that could explain the event (e.g. preexisting 
or concomitant diseases, or co- medications).  
• The event is typi[INVESTIGATOR_771865] -related and infrequent in the general population not 
exposed to drugs (e.g. Stevens-Johnson syndrome). 
• An indication of dose- response  (i.e. greater effect size if the dose is increased, smaller 
effect size if dose is diminished).  
 
Arguments that may suggest that there is no reasonable possibility of a causal relationship 
could be: 
• No plausible time to onset of the event relative to the time of drug exposure is evident 
(e.g. pre -treatment cases, diagnosis of cancer or chronic disease within days/weeks of 
drug administration; an allergic reaction weeks after discontinuation of the drug 
concerned) . 
• Continuation of the event despi[INVESTIGATOR_15576], taking into account 
the pharmacological properties of the compound (e.g. after 5 half -lives).  
Of note, this criterion may not be applicable to events whose time course is prolonged 
despi[INVESTIGATOR_15577]. 
• Additional arguments amongst those stated before, like alternative explanation (e.g. 
situations where other drugs or underlying diseases appear to provide a more likely 
explanation for the observed event than the drug concerned). 
• Disappearance of the event even though the study drug treatment continues or remains unchanged.  
Doc. No.: c23740530-[ADDRESS_1059718] one of the following criteria: 
• Results in death  
• Is life -threatening, which refers to an event in which the patient was at risk of death at the 
time of the event; it does not refer to an event that hypothetically  might have caused 
death if more severe  
• Requires inpatient hospi[INVESTIGATOR_059] , or 
• Requires prolongation of existing hospi[INVESTIGATOR_059] 
• Results in persistent or significant disability or incapacity,  or 
• Is a congenital anomaly o r birth defect, or 
• Is deemed serious  for any other reason if it is an important medical event when based on 
appropriate medical judgment which may jeopardiz e the patient and may require medical 
or surgical intervention to prevent one of the other outcomes listed in the above 
definitions.  
AEs considered “Always Serious”  
In accordance with the European Medicines Agency  (EMA ) initiative on Important Medical 
Events, Boehringer I ngelheim  has set up a list of further AEs, which by [CONTACT_15623], can always 
be considered to be “serious” even though they may not have met the criteria of an SAE as given 
above.  The investigators will be notified of any AE that is entered in the eCRF that meets 
criteria as an Important Medical Event per Always Serious List.  The investigator will promptly 
complete the S AE form with all available information about the AE(s) and report to the 
sponsor’s unique entry point as described in the Investigator Site File ( ISF) immediately (within 
24 hours).  
All SAEs will be reported via Boehringer Ingelheim SAE reporting forms to the Global 
Pharmacovigilance Database.  If patient -level review of claims v ersus site entries reveals any 
hospi[INVESTIGATOR_771866], the investigator will be 
contact[CONTACT_771886]/her.  
7.2.[ADDRESS_1059719] report SAEs on a Boehringer I ngelheim  
SAE form  via the fax form immediately (within 24 hours  of investigator’s awareness of the 
Doc. No.: c23740530-01
Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  32 
 event) as described in the ISF.   The same timeline applies if follow up information becomes 
available.    
Healthcare Claims Database SAE reporting process  
If patient level review of claims database vers us site entries at‘12+3 month mark’ (3 months after 
the 12 month follow- up visit) reveals any hospi[INVESTIGATOR_51531] c laims database that is not already 
captured by  [CONTACT_771887] , the investigator will be contact[CONTACT_771888]. 
The investigator will promptly complete the SAE form with all available information about the 
patient’s hospi[INVESTIGATOR_771867]’s unique entry point as described in the ISF 
immediately (within 24 hours) . 
Information required 
For each AE, the Investigator should provide the information requested on the appropriate eCRF 
pages (if applicable) and Boehringer I ngelheim  SAE Report form. The Investigator should 
determine the causal  relationship to the trial medication . 
The following should also be recorded as S (AE) in the eCRF and SAE form (if applicable):  
• Worsening of pre-existing conditions,  
• Changes in vital signs, electrocardiograms ( ECGs ), physical examinations, and laboratory 
test results, if they are judged clinically relevant by [CONTACT_737].  
If such abnormalities already pre- exist prior to trial inclusion they will be considered as baseline  
conditions. 
7.[ADDRESS_1059720] report immediately any drug exposure during pregnancy.  Drug exposure 
during pregnancy has to be reported immediately (within 24 hours or next business day, whichever is shorter, of the pregnancy becoming known to the investigator) to the defined unique entry point for SAE forms by [CONTACT_771889] A (pregnancy 
monitoring forms and contact [CONTACT_15626]). 
The outcome of the pregnancy associated with the drug exposure must be followed up and 
reported by [CONTACT_771889] B.   
In the absence of an (S)AE, only the Pregnancy Monitoring Form for Clinical Trials and not the 
SAE form is to be completed. 
 
8 DATA COLLECTION  
8.1 Data Sources  
Data sources include demographic and clinical data collected prospectively by [CONTACT_8979], 
patient -completed PRO data and  administrative claims data from patients on  health 
Doc. No.: c23740530-01

Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  33 
 plans (  and targeted non-  health plans.  In order to maintain patient 
confidentiality, each patient will be assigned a unique pat ient study  ID upon enrollment to use in 
place of patient name [CONTACT_39649] (e.g., medical record number).  
Clinical study data, PROs and claims -derived variables will be integrated into one analysis 
dataset via this confidential patient ID.  
The study physician has the ultimate responsibility for the collection and reporting of all clinical 
and patient data through the eCRFs as well as ensuring that they are accurate and complete. 
8.2 eCRFs /EDC  
All clinical study data will be collected at the physician office and entered into eCRF by [CONTACT_771890] a fully validated, 21 CFR 11 and HIPA A complian t EDC system.  
Patients will complete PRO questionnaires ( i.e., CAT) by [CONTACT_771891].  
All study personnel involved in data entry will be trained on patient confidentiality and  the EDC 
system prior to beginning data entry.  Site users will be provided eCRF Completion Guidelines (eCCGs) to assist with study data collection and entry.  Study personnel will access the EDC 
system through a secure study website.  
8.3 Database Development 
All prospectively collected study data will reside in a 21 CFR 11 and HIPAA compliant secure database, developed and managed by  [CONTACT_771892].  Patient- level study data will be 
downloaded from the EDC system to secure  servers for linkage to claims derived variables via a unique patient ID. 
A Clinical Data Manager (CDM) will manage the study database and act as the system 
administrator, creating and maintaining users and database access privileges.  Standard user- type 
privileges will be configured and implemented to ensure privacy and security compliance policy 
requirements.   Patient confidentiality will be strictly maintained.  
A Data Management Plan (DMP) will be developed at the beginning of the study to describe all 
functions, processes and specifications for collection, cleaning and validation of study data from study start up to database lock.   
8.[ADDRESS_1059721] errors in data entry, transfer or transformation accuracy 
throughout the study.  Data quality oversight will involve a multi-t iered process that includes 
electronic edit check specifications, manual checks, self -evident corrections, listing reviews and 
electronic data transfer agreement summaries.   Electronic edit checks will be programmed to 
show discrepancies online at the time of data entry, giving the operator the option to confirm 
acceptance of the discrepant data or change the data.   Manual review and listing reviews will be 
run as outlined in the DMP, either at predetermined intervals or as necessary.   The CDM will 
Doc. No.: c23740530-01

Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  34 
 open queries to resolve any discrepancies  either within the database or directly with study 
personnel.  All changes to existing data will be  fully tracked , maintaining an audit trail report of 
every transaction.  
 
9 STUDY MANAGEMENT  
9.1 Regulatory and Ethical Consideration 
All study activities will be conducted in accordance with regulatory guideline s for real-world, 
pragmatic research.  Study personnel at physician sites will be provided training on the study 
protocol, the ICF, data collection and data entry to ensure both the protection of potential study 
patients as well as the scientific integrity of th e study.   A hybrid approach of both remote and 
onsite monitoring will be employed.  
9.1.1 IRB/Independent Ethics Committee (I EC) 
The study physician will have prospective approval of the study protocol, ICF and any patient 
information or recruiting materials, if applicable, prior to commencement of any study activities.  
In the case of a protocol amendment, the study physician must sign the revised protocol and 
submit the amendment to the IRB/IEC for review and approval prior to implementation of any 
changes specified in the protocol amendment.  All changes in research activity and all unanticipated problems involving risk to human patients or others must be reported promptly to the IRB/IEC . 
The study physician will obtain continued review of the study at intervals not to exceed one year or otherwise specified by [CONTACT_1201]/IEC. 
9.1.2 Informed Consent  
An ICF fully describing the purpose, procedures and potential risks and benefits of the study will 
be developed and approved by [CONTACT_1201]/IEC prior to study initiation.  The study physician must 
ensure that each study patient is fully informed of the study and authorizes release of health 
information prior to study enrollment.  The study physician, or study personnel designated by [CONTACT_5989], will obtain written informed consent from each patient prior to initiation of any study- related procedures.  Each patient will be given a copy of the signed ICF.  The study 
physician will retain the original signed ICF for each patient.  
The IRB/IEC must prospectively approve the ICF and any changes to the ICF during the course of the study before use.  If a protocol amendment alters the study design or increases the potential risk to the patient, the ICF must be revised and submitted to the IRB/IEC for review 
and approval prior to implementation.  The revised ICF must then be used to obtain consent from 
new patients entering the study.  The revised ICF must also be used to obtain consent from 
currently enrolled patients if they a re affected by [CONTACT_29991].  
Doc. No.: c23740530-01
Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  35 
 9.2 Dropouts 
Patient participation is strictly voluntary and patients may refuse to participate or withdraw from 
the study at any time and for any reason.  As such, patients may voluntarily withdraw prior to 
completing the final visit.  In such cases, the study physician will document the specific reason 
for the incomplete information (e.g., withdrawal of consent, lost to follow-up) on the eCRF.  The 
physician should continue follow-up with the patient for any unresolved SAEs. 
9.[ADDRESS_1059722] to audits or evaluations by [CONTACT_771893] (or its designee).  To enable such evaluations and/or audits, the study physician  must 
agree to  maintain and  allow reasonable access to required patient and study records.  The study 
physician agrees to keep the identity of all participating patients (sufficient information to link 
records, e.g., hospi[INVESTIGATOR_1097]), all original signed ICFs , SAE  Forms,  source documents, and 
detailed records of treatment disposition, and adequate documentation of relevant 
correspondence (e.g., letters, m eeting minutes, telephone calls, reports).  The study physician 
should retain records according to local regulations, or as specified in the Clinical Study 
Agreement, whichever is longer. 
 
10 PUBLICATION OF STUDY RESULTS  
All information related to this study is considered confidential information belonging to 
Boehringer Ingelheim  and   A final study report will be generated following 
completion of data collection and analysis.  Results and findings will be submitted to 
conferences and for publication in peer- reviewed scientific journals.  
 
 
Doc. No.: c23740530-01

Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  36 
 Table 1: Time and Events  Schedule  
 Study Visits  
Assessment  or Procedure  Baseline  On Study  
Follow -Up1 EOS  
12 Months  
Written Informed Consent  X   
Eligibility Criteria  X   
Randomization  X   
Demographics  X   
Selected pre-specified comorbid 
conditions  X   
CBC  (Baseline Blood 
Eosinophil Count Required)2 X   
Smoking Status  X   
COPD Diagnosis Date  X   
COPD Exacerbation H istory 
(number and severity of 
exacerbation s in last year)  X   
Pre-Study COPD Therapy  X   
Reason for therapy escalation  X   
COPD Concomitant 
Medications   X X X 
CATTM X   
Study Treatment  X X X 
COPD Exacerbations   X X 
Selected AEs3  X X 
SAEs3  X X 
1The o nly required stud y visits are Baseline and EOS.  Data will be collected at routine clinical 
visits and other patient contact [CONTACT_771894].  
2In the event that a CBC is not available at baseline, laboratory results within 12 months of 
baseline will be accepted.  
3All SAEs and selected AEs will be collected from Baseline through EOS or early termination of 
study participation.   Selected AEs are AEs leading to study treatment discontinuation, dose 
modification  or trial withdrawal.  
Doc. No.: c23740530-01
Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  37 
 Table 2: Sample size calculation s (with number of events) under different assumptions for 
p1, HR and power, 20% non-inferiority margin, one-sided alpha 0.025 and 15% drop- out 
rate during 12 months.  
Scenario  P1 (proportion 
of patients with 
>=1 moderate /severe COPD exacerbation during 12 months in Triple  Therapy  
arm)  P2 (proportion 
of patients with >=1 moderate/  
severe COPD exacerbation during 12 months in 
Stiolto arm)  Expected HR of moderate/  
severe COPD exacerbations between Stiolto and 
Triple  
Therapy  Power  Number of events (moderate/  
severe COPD 
exacerbations ) Sample size 
(total)  
1 40% 39.07%  0.97 95% 1147  3120  
2 42.5%  42.5%  1 90%  1264  3200  
3 45% 46% 1.03 80% [ADDRESS_1059723] for survival analysis. 
 
Doc. No.: c23740530-01
Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  38 
 APPENDIX A: COPD Assessment TestTM (CAT) 
 
Doc. No.: c23740530-01

Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  39 
  Summary of Amendments and Updates  
 
Summary of Changes 
1237-0064 Protocol Version 2.0, dated 09May2018 
 
Number  Section/Page  
 Change  Rationale  
1 Global Change  
 May 9 , 2018 June 7, 2017  
 
Version 1 2.0 
 Updated protocol date and 
version. 
2 Study Approvals, 
page 2  Sponsor Approval : 
 
Name:  
 
[CONTACT_1641]:  
 of 
Clin
ical Development & 
Medical 
A
ffairs, Primary Care - 
Respi[INVESTIGATOR_771868] & 
Asthma  
 
 Updated sponsor Principal 
Investigator [INVESTIGATOR_771869]. 
3 Synopsis Study 
Procedures, page 9  
 • A complete blood count 
(CBC) including differential 
white cell count will be drawn at baseline. 
In the 
event that a CBC is not 
available at baseline, 
laboratory results within [ADDRESS_1059724] care.  
 Removed sentence to allow 
additional patient outreach at study sites to increase study enrollment.  
5 Section 4 Study 
Design  To enhance enrollment at trial 
initiation, up to 500 non -  Deleted sentences to remove 
any restriction from 
Doc. No.: c23740530-01

Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  40 
 4.2.2 Part icipant 
Recruitment and 
Eligibility, page 18  patients will be allowed to 
enroll, following which 
enrollment will be restricted to 
 patients only if 
possible.  In such event that 
additional non-  patients 
are needed to complete 
enrollment, the decision to re-
open enrollment to non-  
patients will be made jointly 
between  and 
Boehringer Ingelheim. 
 enrollment of non -  
patients to increase study enrollment.  
6 Figure 1: 
Schematic of Study Design, page 20 • Identify Eeligible  
patient s interacts with 
physician in course of 
normal care  Modified sentence to allow 
additional patient outreach at study sites to increase study enrollment, consistent with change #4 in 4.2.2 above 
 
7 Section 5 Study 
Procedures  
5.2 Baseline Visit, page 21 A blood sample will be drawn 
at the baseline visit for a complete blood count (CBC) including differential white cell count.  
In the event that a CBC 
is not available at baseline, 
laboratory results within 12 
months of baseline will be 
accepted . 
 Added language to relax the 
timing required for a baseline CBC. This change increases the flexibility of study requirements and is consistent with the pr agmatic 
design. 
8 Table 1: Time and 
Events Schedule, page 36 
 CBC (Baseline Blood 
Eosinophil Count Required)2 
 
2In the event that a CBC is not 
available at baseline, laboratory 
results within 12 months of 
baseline will be accepted.  
 Added footnote to relax the 
timing required for a baseline 
CBC. This change increases the flexibility of study requirements and is consistent with the pragmatic design, and consistent with changes #3 and #7 in Study Procedures above.  
 
9 Table 1: Time and 
Events Schedule, page 36  
 Selected AEs23 
SAEs23 
 
23All SAEs and selected AEs 
will be collected from Baseline 
through EOS or early termination of study Updated footnote numbering 
to accommodate addition of 
footnote in change #8. 
Doc. No.: c23740530-01

Boehringer Ingelheim   Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 CONFIDENTIAL  41 
 participation.  Selected AEs are 
AEs leading to study treatment 
discontinuation, dose 
modification or trial withdrawal.  
 
 
 
Doc. No.: c23740530-01
   
 
APPROVAL / SIGNATURE [CONTACT_15650]:  Technical Version Number:  
Document Name:  
  
                                                                                                                  
[CONTACT_1641]:  
 
 
 
                                                                                                                    
Signatures (obtained electronically) 
 
Meaning of Signature  [CONTACT_9719] [CONTACT_9716] 
 
  
  
   
 
  
  
   
 
  
  
   
 
  
  
   
 
  
  
   
 
  
  
   
 
  
  
   
 
  
  
 c23740530 1.0
clinical-trial-protocol-version-2
Randomized Pragmatic Clinical in Trial in a Community-Based Setting Comparing
STIOLTO RESPI[INVESTIGATOR_771870]. ICS-LABA plus LAMA in Patients with COPD   TheAIRWISE Study: Assessment In a Real World setting of the effect of Inhaled Steroidbased triple therapy versus the combination of tiotropi[INVESTIGATOR_771871]-Clinical Monitor 08 Jun 2018 12:[ADDRESS_1059725]

Boehringer Ingelheim Page  2 of 2
Document Number:  Technical Version Number :  
 
 (Continued) Signatures (obtained electronically) 
 
Meaning of Signature  [CONTACT_9719] [CONTACT_9716] 
 
   
  
 
 
  
  
  
 
  
 
    
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
 c23740530 1.0